As the company continues to expand its pipeline of antibody drug conjugates
ADC Therapeutics (ADCT), a Swiss oncology drug development company focused on Antibody Drug Conjugates (ADCs) targeting major cancers, has significantly expanded its team.
Jay Feingold joins as Chief Medical Officer and Head of Oncology Clinical Development. He has more than 25 years of industry, academic and medical experience and was most recently Vice President, US Medical Affairs and Chairman Global Medical Affairs Oversight Committee at Daiichi Sankyo. Prior to this, he was Vice President of Clinical Development, Global Therapy Area Director, Oncology at Wyeth.
Michael Mulkerrin, who joins as Head of CMC (Chemistry Manufacturing and Control), has more than 20 years of industry experience in biologics manufacturing, most recently as Vice President, Process Development and Manufacturing at OncoMed.
Simon Chivers has been appointed as Head of Toxicology. He has more than 15 years of industry experience, most recently as Global Head Biologics Safety Assessment and Executive Director at Novartis.
Lisa Skelton has become Senior Project Manager for ADCT’s lead programme ADCT-301. She has more than 20 years of industry experience, most recently as Associate Director, Programme Management at Norgine and Senior Programme Manager at Amgen.
Karin Havenith joins as Senior Bioanalytical Scientist to head ADCT’s bioanalytical group. She was formerly Principal Scientist at J&J Janssen Crucell and Principal Scientist at Genmab where she specialised in the development of bioanalytical assays for antibody therapeutics.
Francesca Zammarchi has come to the scientific team as Cancer Biologist, having spent eight years as a Research Associate in the Molecular Pharmacology and Chemistry Department of Memorial Sloan Kettering Cancer Centre, New York.
Dulce Gonçalves joins as Corporate Counsel and was most recently Senior Legal Counsel, Global Product Strategy and Commercialisation, at Novartis.
Stéphane Henchoz has been appointed as Director of Finance. He brings more than 20 years of pharmaceutical industry finance experience to the company, most recently working at Merck Serono.
Michael Forer, Chief Executive of ADC Therapeutics, said: 'The quality of individuals and depth of experience that we have been able to attract demonstrates the significant potential for our PBD-based ADCs.
'This expansion underlines the progress we have made since the company was established in early 2012. We continue to advance our pipeline of programmes into clinical development with our lead programme, ADCT-301, scheduled to enter clinical development in early 2015.'